002793 罗欣药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.360-22.667-50.127-23.425-32.408
总资产报酬率 ROA (%)1.361-7.160-20.426-9.990-13.907
投入资产回报率 ROIC (%)1.702-9.045-25.427-11.791-16.802

边际利润分析
销售毛利率 (%)60.53049.64942.14446.27826.741
营业利润率 (%)6.847-13.207-36.206-24.810-40.667
息税前利润/营业总收入 (%)8.404-10.253-33.828-22.876-37.463
净利润/营业总收入 (%)4.639-12.515-39.747-32.528-35.046

收益指标分析
经营活动净收益/利润总额(%)104.36483.26849.07672.963111.686
价值变动净收益/利润总额(%)18.30016.73322.730-1.902-11.182
营业外收支净额/利润总额(%)-6.906-3.224-0.5922.9190.274

偿债能力分析
流动比率 (X)0.7910.8390.7031.0781.079
速动比率 (X)0.6350.6990.5220.8410.923
资产负债率 (%)66.72466.83066.34249.73259.265
带息债务/全部投入资本 (%)58.73957.43453.47736.20051.356
股东权益/带息债务 (%)66.10768.27575.750163.14987.912
股东权益/负债合计 (%)46.69746.75648.05397.04965.983
利息保障倍数 (X)4.203-4.035-15.628-8.536-11.299

营运能力分析
应收账款周转天数 (天)53.71879.05073.000104.563200.819
存货周转天数 (天)137.115123.151107.551161.67095.476